Impact Of Dose-dense Administration Of Cisplatin And Paclitaxel On The Repopulation Of Skov3Cells And Its Effect On Recurrent Ovarian Cancer Patients With Platinum-resistance

Objectives: To compare the impact of different treatment schedule ofcisplatin (CDDP) or/and paclitaxel (PTX) on the repopulation of SKOV3cells, and to observe the response of the refractory ovarian cancer patientsto the dose-dense administration in the clinical practice.Methods:1. The repopulation of SKOV3cells treated with CDDPor/and PTX given as A (the total dose dividedly dosed on day1(D1) andD8) or B (the same total dose for a single dose administration on D1) wasobserved under microscope; and CCK-8method was used to detect thecell survival of different arms on D7and D21.2. A total of20cases ofovarian cancer patients recurring with platinum-resistance or presentingwith refractory disease initially received a dose-dense administration ofCDDP and PTX as below: CDDP90mg/m2dividely dosed on D1, D2,D3+PTX175mg/m2dividely dosed on D1, D8; and then the therapeuticeffect of this schedule was estimated.Results:11.1In CDDP groups, no significant difference was foundbetween Schedule A and B (F=70.421，p=0.970);1.2In PTX groups andCDDP plus PTX groups, the repopulation of SKOV3cells was bothstrikingly inhibited in Schedule B compared with A (F=1872.275，p=0.000;F=1633.565，p=0.000), and such suppressive efficiency was even moreevident in the combinative group (F=2500.464， p=0.000).22.1Among theses20patients who received this dose-dense schedule,15presented with clinical response (15/20,75%), and a complete responsewas observed in5patients (5/20,25%);2.2The main adverse reaction ofthis schedule included myelosupression and gastrointestinal toxicity,however, most patients could tolerate with symptomatic treatment.Conclusions: Our results of cytological experiment implies thatcombinative treatment with CDDP and PTX given on D1and D8withoutan increase in total dose might inhibit the repopulation of SKOV3cells.Furthermore, our clinical observation demonstrated such administrationworked for most patients with refractory ovarian cancer. However, themechanism and the feasibility of clinical application need furtheridentifying.